Sotera Health Company (SHC) reported $303.44 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 4.6%. EPS of $0.26 for the same period compares to $0.21 a year ago.
The reported revenue represents a surprise of +1.4% over the Zacks Consensus Estimate of $299.26 million. With the consensus EPS estimate being $0.24, the EPS surprise was +7.22%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $198.41 million versus $195.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
- Net Revenues- Nelson Labs: $55.2 million versus the three-analyst average estimate of $55.48 million. The reported number represents a year-over-year change of +2.3%.
- Net Revenues- Nordion: $49.83 million versus the three-analyst average estimate of $48.33 million. The reported number represents a year-over-year change of -12.3%.
View all Key Company Metrics for Sotera Health here>>>
Shares of Sotera Health have returned -5.9% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sotera Health Company (SHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
